Extensive, late-stage radiopharmaceutical pipeline

Our core product pipeline, focused on  urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning has generated extensive clinical data that demonstrate the potential for efficacy and good safety profile. We believe the targets and indications we are pursuing are well validated and are well suited for the delivery of therapeutic and diagnostic targeted radiation. The use of imaging to select patients for therapy is also a differentiated aspect of our commercial strategy.

Prostate

PSMA1
TARGETING
AGENT
ISOTOPE
Dx/Tx4
PRE-CLINICAL
PHASE I
PHASE II
PHASE III
COMMERCIAL
Antibody
177Lu
Tx
TLX591 (177Lu rosopatamab tetraxetan)
Antibody
225Ac (alpha)
Tx
TLX592 (225Ac-RADmAb®)
Small molecule
68Ga
Dx
Illuccix® (68Ga-PSMA-11)
Small molecule
68Ga
Dx
TLX007-CDx
Kidney + other

CAIX2
TARGETING
AGENT
ISOTOPE
Dx/Tx4
PRE-CLINICAL
PHASE I
PHASE II
PHASE III
COMMERCIAL
Antibody
177Lu
Tx
TLX250 (177Lu-girentuximab)
Antibody
225Ac (alpha)
Tx
TLX252 (225Ac-girentuximab)
Antibody
89Zr
Dx
Zircaix®5 (89Zr-girentuximab)
Brain

LAT1 & LAT23
TARGETING
AGENT
ISOTOPE
Dx/Tx4
PRE-CLINICAL
PHASE I
PHASE II
PHASE III
COMMERCIAL
Small molecule
131I
Tx
TLX101 (131I-IPA)
Small molecule
211At (alpha)
Tx
TLX102 (211At-APA)
Small molecule
18F
Dx
Pixclara®5 (18F-floretyrosine)
Musculo-skeletal
TARGETING
AGENT
ISOTOPE
Dx/Tx4
PRE-CLINICAL
PHASE I
PHASE II
PHASE III
COMMERCIAL
Antibody
90Y
Tx
TLX66 (90Y-besilesomab), CD666 targeting agent for bone-marrow conditioning for haematological diseases
Antibody
99mTc
Dx
TLX66-CDx (99mTc-besilesomab, Scintimun®), CD66 imaging agent for osteomyelitis (bone infection)
Small molecule
153Sm
Tx
TLX090 (153Sm-DOTMP), bone-seeking agent for bone metastases and pain palliation
Antibody
Undisclosed
Tx
TLX300 (-olaratumab), PDGFRα7 targeting radio antibody-drug conjugate for soft-tissue sarcoma (STS) treatment

1. Prostate-specific membrane antigen.
2. Carbonic anhydrase IX.
3. L-type amino acid transporters 1 and 2.
4. Dx = diagnostic; Tx = therapeutic.
5. Brand name subject to final regulatory approval.
6. Cluster of differentiation 66.
7. Platelet derived growth factor receptor alpha.